Streamlining Regulatory Audit Readiness for CRISPR-Mediated Gene Therapy Development
Before transfer to a clinical environment, CRISPR-edited gene therapies are subject to internal and external regulatory audits. Advancement into clinical studies requires comprehensive data reporting and analysis to demonstrate that manufacturing and analytical workflows are followed and fully documented. GxP-compliant data management capabilities and structured documentation of CQAs provided by the Genedata Biopharma Platform support regulatory readiness by facilitating standardized data capture, traceability and alignment with CMC expectations for gene therapy submissions. Reporting tools within IDBS Polar Biopharma Lifecycle Management software, saving time and deliver complete reports for pre-IND and post-IND regulatory submissions while maintaining data provenance and auditability.